Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIALIZE-Outcomes
2020-005561-14Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia comparing Sodium zirconium cyclosilicate with Placebo (2 arms). Primary endpoint: Time to first occurrence of sudden cardiac death, stroke, or hospitalization/intervention/emergency department visit due to arrhythmias. Started Mar 2021; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2020-005561-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005561-14.